TD Asset Management Inc Takes Position in Inspire Medical Systems, Inc. (NYSE:INSP)

TD Asset Management Inc acquired a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSPFree Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 9,600 shares of the company’s stock, valued at approximately $1,953,000.

Several other hedge funds have also recently made changes to their positions in INSP. McGlone Suttner Wealth Management Inc. bought a new position in Inspire Medical Systems in the fourth quarter valued at about $27,000. Headinvest LLC bought a new position in shares of Inspire Medical Systems in the 3rd quarter worth approximately $48,000. Principal Securities Inc. purchased a new position in shares of Inspire Medical Systems in the fourth quarter worth approximately $54,000. International Assets Investment Management LLC purchased a new position in shares of Inspire Medical Systems in the fourth quarter worth approximately $166,000. Finally, Van ECK Associates Corp grew its position in Inspire Medical Systems by 26.4% during the third quarter. Van ECK Associates Corp now owns 853 shares of the company’s stock valued at $169,000 after buying an additional 178 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Inspire Medical Systems

In related news, Director Jerry C. Griffin sold 554 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $198.05, for a total transaction of $109,719.70. Following the completion of the transaction, the director now directly owns 9,744 shares of the company’s stock, valued at $1,929,799.20. The sale was disclosed in a filing with the SEC, which is available through this link. In other Inspire Medical Systems news, Director Jerry C. Griffin sold 554 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $198.05, for a total transaction of $109,719.70. Following the completion of the transaction, the director now owns 9,744 shares in the company, valued at $1,929,799.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO John Rondoni sold 4,387 shares of the business’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $194.40, for a total transaction of $852,832.80. Following the completion of the sale, the chief technology officer now owns 11,270 shares in the company, valued at $2,190,888. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,081 shares of company stock valued at $12,840,253. 4.10% of the stock is currently owned by insiders.

Inspire Medical Systems Price Performance

Inspire Medical Systems stock opened at $157.79 on Friday. Inspire Medical Systems, Inc. has a 1 year low of $123.27 and a 1 year high of $330.00. The firm’s 50 day moving average price is $198.34 and its 200-day moving average price is $192.17. The stock has a market cap of $4.69 billion, a P/E ratio of -286.89 and a beta of 1.33.

Inspire Medical Systems (NYSE:INSPGet Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.29. Inspire Medical Systems had a negative net margin of 2.38% and a negative return on equity of 2.82%. The company had revenue of $164.01 million during the quarter, compared to analysts’ expectations of $161.41 million. During the same period last year, the company posted ($0.53) earnings per share. Inspire Medical Systems’s quarterly revenue was up 28.2% on a year-over-year basis. As a group, equities analysts expect that Inspire Medical Systems, Inc. will post 0.16 EPS for the current year.

Analyst Upgrades and Downgrades

INSP has been the topic of several recent research reports. Truist Financial reiterated a “buy” rating and issued a $280.00 price target on shares of Inspire Medical Systems in a research report on Wednesday, March 20th. Mizuho reiterated a “buy” rating and set a $250.00 target price on shares of Inspire Medical Systems in a research report on Wednesday, March 27th. Royal Bank of Canada initiated coverage on Inspire Medical Systems in a report on Friday, April 19th. They set an “outperform” rating and a $285.00 price target for the company. Bank of America decreased their price objective on Inspire Medical Systems from $225.00 to $185.00 and set a “neutral” rating on the stock in a research note on Monday, June 3rd. Finally, Morgan Stanley started coverage on Inspire Medical Systems in a research report on Tuesday, March 19th. They set an “overweight” rating and a $250.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $253.87.

View Our Latest Report on INSP

Inspire Medical Systems Company Profile

(Free Report)

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

See Also

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSPFree Report).

Institutional Ownership by Quarter for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.